转移性胰腺腺癌的治疗：全面综述

Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.

作者信息

Kozuch P, Petryk M, Evans A, Bruckner H W

机构信息

Division of Medical Oncology, St. Luke's-Roosevelt Hospital Center, Columbia University, New York, New York 10019, USA.

出版信息

Surg Clin North Am. 2001 Jun;81(3):683-90. doi: 10.1016/s0039-6109(05)70153-5.

DOI:10.1016/s0039-6109(05)70153-5

PMID:11459281

Abstract

The current standard therapy for metastatic pancreatic adenocarcinoma is the single-agent gemcitabine, by the increasingly used fixed rate infusion of 10 mg/m2/min. There is strong reason to anticipate that additional benefits will accrue with gemcitabine-based combination chemotherapy. Gemcitabine and CPT-11 are synergistic with many drugs and non-cross-resistant with each other. Rigorous clinical investigations will be performed in an effort to identify optimal drug sequence and schedules for these novel combinations.

摘要

转移性胰腺腺癌目前的标准治疗方法是使用单药吉西他滨，采用越来越常用的10mg/m²/分钟的固定速率输注。有充分理由预期，基于吉西他滨的联合化疗将带来更多益处。吉西他滨和CPT-11与许多药物具有协同作用，且彼此无交叉耐药性。将开展严格的临床研究，以确定这些新联合方案的最佳用药顺序和疗程。